<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The paper presented a case of a patient with type III by FAB <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, in whom during a low dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> therapy <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> occurred </plain></SENT>
<SENT sid="1" pm="."><plain>Authors discussed roles of <z:hpo ids='HP_0001903'>anemia</z:hpo>, <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> and <z:hpo ids='HP_0002900'>hypokalemia</z:hpo> as factors which could increase circulatory system sensitivity on <z:chebi fb="0" ids="28680">cytarabine</z:chebi> action </plain></SENT>
</text></document>